Bayer(US:BAYRY) 生物世界·2025-08-14 04:49Core Viewpoint - The article emphasizes the significant advancements and opportunities in China's pharmaceutical innovation landscape, particularly through collaborations with multinational companies like Bayer, which aims to discover the next major innovation in the industry [1][3]. Summary by Sections Innovation Landscape - China leads globally in pharmaceutical patent applications with a 43% share in 2024, and the number of drug pipelines in development exceeds 7,000, accounting for approximately 30% of the global total [1]. - The initiation of clinical trials for oncology by Chinese companies represents 39% of the global total, positioning China at the forefront of cancer research [1]. Collaboration and Investment - Chinese companies are increasingly engaging in high-value transactions with multinational pharmaceutical firms, with 37% of transactions involving upfront payments exceeding $50 million originating from China [2]. - In the cardiovascular and metabolic fields, the total upfront payments from Chinese companies to multinational firms have reached $6.85 billion in 2024 [2]. Bayer's Initiative - Bayer is actively investing in China's innovation ecosystem through the "Co-Creation New Drug" competition, which has garnered significant attention and support from the industry since its launch in July 2025 [3]. - The competition invites submissions of innovative drug candidates and technologies, with a focus on areas such as precision oncology, immunology, and gene therapy [4][5]. Competition Timeline and Evaluation - The application deadline for the competition is August 31, 2025, followed by a series of evaluations and presentations leading to the announcement of winners by the end of October [7]. - Submissions will be assessed by a committee of Bayer's R&D and business development experts based on innovation level, key data, and alignment with Bayer's strategic goals [6]. Rewards for Winners - Winners of the competition will receive various benefits, including access to Bayer's Co.Lab, opportunities for face-to-face meetings with global executives, and participation in global roadshows [8][10].